AERI - Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc.

4301 Emperor Boulevard
Suite 400
Durham, NC 27703
United States
919-237-5300
http://www.aeriepharma.com

Sector: Healthcare
Industry: Drug Manufacturers - Major
Full Time Employees: 353

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Vicente J. Anido Jr.	CEO & Chairman	1.16M	11.84M	1953
Mr. Thomas A. Mitro	Pres & COO	621k	10.85M	1958
Dr. Casey C. Kopczynski	Co-Founder & Chief Scientific Officer	578.03k	169.56k	1961
Mr. Richard James Rubino CPA	CFO, Sec. & Treasurer	631.12k	N/A	1958
Mr. John W. LaRocca Esq.	Gen. Counsel & Assistant Sec.	521.07k	N/A	1965

Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Corporate Governance

Aerie Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.